Loading...
Header Logo
Keywords
Last Name
Institution

BEDRICH ECKHARDT

TitleInstructor
InstitutionMD Anderson
DepartmentBreast Medical Oncology
vCardDownload vCard

    Collapse ORNG Applications 
    Collapse Verify Publications

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Espinosa Fernandez JR, Eckhardt BL, Lee J, Lim B, Pearson T, Seitz RS, Hout DR, Schweitzer BL, Nielsen TJ, Lawrence OR, Wang Y, Rao A, Ueno NT. Identification of triple-negative breast cancer cell lines classified under the same molecular subtype using different molecular characterization techniques: Implications for translational research. PLoS One. 2020; 15(4):e0231953. PMID: 32353087.
      View in: PubMed
    2. Hayward S, Gachehiladze M, Badr N, Andrijes R, Molostvov G, Paniushkina L, Sopikova B, Slobodová Z, Mgebrishvili G, Sharma N, Horimoto Y, Burg D, Robertson G, Hanby A, Hoar F, Rea D, Eckhardt BL, Ueno NT, Nazarenko I, Long HM, van Laere S, Shaaban AM, Berditchevski F. The CD151-midkine pathway regulates the immune microenvironment in inflammatory breast cancer. J Pathol. 2020 May; 251(1):63-73. PMID: 32129471.
      View in: PubMed
    3. Eckhardt BL, Cao Y, Redfern AD, Chi LH, Burrows AD, Roslan S, Sloan EK, Parker BS, Loi S, Ueno NT, Lau PKH, Latham B, Anderson RL. Activation of Canonical BMP4-SMAD7 Signaling Suppresses Breast Cancer Metastasis. Cancer Res. 2020 Mar 15; 80(6):1304-1315. PMID: 31941699.
      View in: PubMed
    4. Torres-Adorno AM, Vitrac H, Qi Y, Tan L, Levental KR, Fan YY, Yang P, Chapkin RS, Eckhardt BL, Ueno NT. Eicosapentaenoic acid in combination with EPHA2 inhibition shows efficacy in preclinical models of triple-negative breast cancer by disrupting cellular cholesterol efflux. Oncogene. 2019 03; 38(12):2135-2150. PMID: 30459358.
      View in: PubMed
    5. Eckhardt BL, Gagliardi M, Iles L, Evans K, Ivan C, Liu X, Liu CG, Souza G, Rao A, Meric-Bernstam F, Ueno NT, Bartholomeusz GA. Clinically relevant inflammatory breast cancer patient-derived xenograft-derived ex vivo model for evaluation of tumor-specific therapies. PLoS One. 2018; 13(5):e0195932. PMID: 29768500.
      View in: PubMed
    6. Steigedal TS, Toraskar J, Redvers RP, Valla M, Magnussen SN, Bofin AM, Opdahl S, Lundgren S, Eckhardt BL, Lamar JM, Doherty J, Hynes RO, Anderson RL, Svineng G. Nephronectin is Correlated with Poor Prognosis in Breast Cancer and Promotes Metastasis via its Integrin-Binding Motifs. Neoplasia. 2018 04; 20(4):387-400. PMID: 29539586.
      View in: PubMed
    7. Wang X, Reyes ME, Zhang D, Funakoshi Y, Trape AP, Gong Y, Kogawa T, Eckhardt BL, Masuda H, Pirman DA, Yang P, Reuben JM, Woodward WA, Bartholomeusz C, Hortobagyi GN, Tripathy D, Ueno NT. EGFR signaling promotes inflammation and cancer stem-like activity in inflammatory breast cancer. Oncotarget. 2017 Sep 15; 8(40):67904-67917. PMID: 28978083.
      View in: PubMed
    8. Eckhardt BL, Ueno NT. A target of potential RELAvance in inflammatory breast cancer. Oncotarget. 2017 04 18; 8(16):25835-25836. PMID: 28460487.
      View in: PubMed
    9. Reyes ME, Fujii T, Branstetter D, Krishnamurthy S, Masuda H, Wang X, Reuben JM, Woodward WA, Edwards BJ, Hortobagyi GN, Tripathy D, Dougall WC, Eckhardt BL, Ueno NT. Poor prognosis of patients with triple-negative breast cancer can be stratified by RANK and RANKL dual expression. Breast Cancer Res Treat. 2017 Jul; 164(1):57-67. PMID: 28417335.
      View in: PubMed
    10. Dobroff AS, D'Angelo S, Eckhardt BL, Ferrara F, Staquicini DI, Cardó-Vila M, Staquicini FI, Nunes DN, Kim K, Driessen WHP, Hajitou A, Lomo LC, Barry M, Krishnamurthy S, Sahin A, Woodward WA, Prossnitz ER, Anderson RL, Dias-Neto E, Brown-Glaberman UA, Royce ME, Ueno NT, Cristofanilli M, Hortobagyi GN, Marchiò S, Gelovani JG, Sidman RL, Arap W, Pasqualini R. Towards a transcriptome-based theranostic platform for unfavorable breast cancer phenotypes. Proc Natl Acad Sci U S A. 2016 Nov 08; 113(45):12780-12785. PMID: 27791177.
      View in: PubMed
    11. Le Du F, Eckhardt BL, Lim B, Litton JK, Moulder S, Meric-Bernstam F, Gonzalez-Angulo AM, Ueno NT. Is the future of personalized therapy in triple-negative breast cancer based on molecular subtype? Oncotarget. 2015 May 30; 6(15):12890-908. PMID: 25973541.
      View in: PubMed
    12. Johnstone CN, Smith YE, Cao Y, Burrows AD, Cross RS, Ling X, Redvers RP, Doherty JP, Eckhardt BL, Natoli AL, Restall CM, Lucas E, Pearson HB, Deb S, Britt KL, Rizzitelli A, Li J, Harmey JH, Pouliot N, Anderson RL. Functional and molecular characterisation of EO771.LMB tumours, a new C57BL/6-mouse-derived model of spontaneously metastatic mammary cancer. Dis Model Mech. 2015 Mar; 8(3):237-51. PMID: 25633981.
      View in: PubMed
    13. Cao Y, Slaney CY, Bidwell BN, Parker BS, Johnstone CN, Rautela J, Eckhardt BL, Anderson RL. BMP4 inhibits breast cancer metastasis by blocking myeloid-derived suppressor cell activity. Cancer Res. 2014 Sep 15; 74(18):5091-102. PMID: 25224959.
      View in: PubMed
    14. Miao YR, Eckhardt BL, Cao Y, Pasqualini R, Argani P, Arap W, Ramsay RG, Anderson RL. Inhibition of established micrometastases by targeted drug delivery via cell surface-associated GRP78. Clin Cancer Res. 2013 Apr 15; 19(8):2107-16. PMID: 23470966.
      View in: PubMed
    15. Eckhardt BL, Francis PA, Parker BS, Anderson RL. Strategies for the discovery and development of therapies for metastatic breast cancer. Nat Rev Drug Discov. 2012 Jun 01; 11(6):479-97. PMID: 22653217.
      View in: PubMed
    16. Carraro DM, Ferreira EN, de Campos Molina G, Puga RD, Abrantes EF, Trapé AP, Eckhardt BL, Ekhardt BL, Nunes DN, Brentani MM, Arap W, Pasqualini R, Brentani H, Dias-Neto E, Brentani RR. Poly (A)+ transcriptome assessment of ERBB2-induced alterations in breast cell lines. PLoS One. 2011; 6(6):e21022. PMID: 21731642.
      View in: PubMed
    17. Karjalainen K, Jaalouk DE, Bueso-Ramos CE, Zurita AJ, Kuniyasu A, Eckhardt BL, Marini FC, Lichtiger B, O'Brien S, Kantarjian HM, Cortes JE, Koivunen E, Arap W, Pasqualini R. Targeting neuropilin-1 in human leukemia and lymphoma. Blood. 2011 Jan 20; 117(3):920-7. PMID: 21063027.
      View in: PubMed
    18. Parker BS, Ciocca DR, Bidwell BN, Gago FE, Fanelli MA, George J, Slavin JL, Möller A, Steel R, Pouliot N, Eckhardt B, Henderson MA, Anderson RL. Primary tumour expression of the cysteine cathepsin inhibitor Stefin A inhibits distant metastasis in breast cancer. J Pathol. 2008 Feb; 214(3):337-46. PMID: 17985332.
      View in: PubMed
    19. Sidor C, D'Amato R, Miller KD. The potential and suitability of 2-methoxyestradiol in cancer therapy. Clin Cancer Res. 2005 Aug 15; 11(16):6094-5; author reply 6095-6. PMID: 16115955.
      View in: PubMed
    20. Sutherland TE, Schuliga M, Harris T, Eckhardt BL, Anderson RL, Quan L, Stewart AG. 2-methoxyestradiol is an estrogen receptor agonist that supports tumor growth in murine xenograft models of breast cancer. Clin Cancer Res. 2005 Mar 01; 11(5):1722-32. PMID: 15755993.
      View in: PubMed
    21. Eckhardt BL, Parker BS, van Laar RK, Restall CM, Natoli AL, Tavaria MD, Stanley KL, Sloan EK, Moseley JM, Anderson RL. Genomic analysis of a spontaneous model of breast cancer metastasis to bone reveals a role for the extracellular matrix. Mol Cancer Res. 2005 Jan; 3(1):1-13. PMID: 15671244.
      View in: PubMed
    22. Chung RS, Vickers JC, Chuah MI, Eckhardt BL, West AK. Metallothionein-III inhibits initial neurite formation in developing neurons as well as postinjury, regenerative neurite sprouting. Exp Neurol. 2002 Nov; 178(1):1-12. PMID: 12460603.
      View in: PubMed
    23. Chung RS, Holloway AF, Eckhardt BL, Harris JA, Vickers JC, Chuah MI, West AK. Sheep have an unusual variant of the brain-specific metallothionein, metallothionein-III. Biochem J. 2002 Jul 01; 365(Pt 1):323-8. PMID: 11931634.
      View in: PubMed
    24. Erratum. Biochemical Journal. 365:903.
    25. Is the future of personalized therapy in triple-negative breast cancer based on molecular subtype?. Oncotarget. 6:12890-12908.
    26. Towards a transcriptome-based theranostic platform for unfavorable breast cancer phenotypes. Proceedings of the National Academy of Sciences of the United States of America. 113:12780-12785.
    ECKHARDT's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Co-Authors Expand Description
    _
    Similar People Expand Description
    _
    Same Department Expand Description